Up until the present, there are no predictive biomarkers or indicators for guiding the HNSCC treatment. A survey report on precision medicine entitled, “Global Precision Medicine Market – Analysis and Forecast, 2017–2026” from BIS research registered $43.59 billion in 2016. It is estimated to reach $141.70 billion by 2026, with an annual growth rate of 11.23%. The Personalized Medicine Coalition for diagnostic and targeted agents was $25 billion in 2015. 

“On a thumb rule, 30% of new Cancer screened cases would account for HNSCC, the majority of men affected by it.”Dr Hemantkumar Nemade
Consultant Head and Neck Oncologist
Basavatarakam Indo-American
Cancer Hospital,Hyderabad

The biomarkers for precision medicine drugs (in numbers) were 5 in 2008 and went up to 132 in 2016. According to a survey by The Tufts Centre for Drug Development. 42% of drugs are in the pipeline plan and will be considered soon. Global investments in the next 5 years are likely to increase by 33% for precision medicine drugs, and immunotherapy drugs. There is a surge in the global market where the growth was $108 billion in 2016 and is nearly estimated to be $200 billion by 2021 . . .